# A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

> **NCT03869684** · PHASE2 · TERMINATED · sponsor: **Senju Pharmaceutical Co., Ltd.** · enrollment: 13 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** MT-0814
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03869684
- **Lead sponsor:** Senju Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-25
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-04-24
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study terminated for safety reasons
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869684, "A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03869684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*